Ocuphire Pharma Results

Majority of Physicians Use a "Wait and Monitor" Approach for DR Patients Over 90% of DR Patients Are Not Treated Proactively and Anti-VEGF Use is Limited Ocuphire PHARMA How do physicians treat patients with severe NPDR without DME? Closely monitor retinopathy and encourage systemic glycemic control Consider anti-VEGF in some patients with poor glycemic control and/or other risks Consider anti-VEGF in some patients with good glycemic control and compliance Consider anti-VEGF therapy in all or most patients Source: ASRS 2021 Preferences and Trends (PAT) Survey Other 4.9% 3.1% 7.7% 7.8% 10.9% 3.7% 17.0% 24.9% 0.00% 10.00% 20.00% 30.00% 40.00% 50.00% International US 59.5% 60.5% 60.00% 70.00% 18

View entire presentation